Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I... Drugs R D (2018) 18:149–159 https://doi.org/10.1007/s40268-018-0236-x ORIGINAL RESEARCH ARTICLE Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers 1 1 1 2 • • • • Marie Cullberg Cecilia Arfvidsson Bengt Larsson Anna Malmgren 3 1 1 • • Patrick Mitchell Ulrika Wa ¨ hlby Hamre ´n Heather Wray Published online: 31 May 2018 The Author(s) 2018 Abstract Intra- and inter-subject variability in AUC was 3–11 and Objective The aim of this study was to summarise the 29–64%, respectively. Less than 5% of the AZD5069 dose pharmacokinetic findings from eight phase I studies in was excreted as parent drug in the urine. Elderly subjects healthy volunteers given oral AZD5069, a selective small- had 39% higher AZD5069 AUC and 21% higher C than max molecule CXCR2 antagonist. younger adults. Japanese subjects had similar or slightly Methods 240 healthy volunteers across eight phase I higher exposure to AZD5069 than Caucasian subjects. Co- studies received single (0.1–200 mg) or multiple once- or administration with ketoconazole resulted in 2.1-fold twice-daily (10–120 mg) oral AZD5069 as solution, sus- higher AUC and 1.6-fold higher C . All formulations had max pension, capsules or tablets. Pharmacokinetics were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs in R&D Springer Journals

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/pharmacokinetics-of-the-oral-selective-cxcr2-antagonist-azd5069-a-0AYPl3TyV0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
1174-5886
eISSN
1179-6901
DOI
10.1007/s40268-018-0236-x
pmid
29856004
Publisher site
See Article on Publisher Site

Abstract

Drugs R D (2018) 18:149–159 https://doi.org/10.1007/s40268-018-0236-x ORIGINAL RESEARCH ARTICLE Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers 1 1 1 2 • • • • Marie Cullberg Cecilia Arfvidsson Bengt Larsson Anna Malmgren 3 1 1 • • Patrick Mitchell Ulrika Wa ¨ hlby Hamre ´n Heather Wray Published online: 31 May 2018 The Author(s) 2018 Abstract Intra- and inter-subject variability in AUC was 3–11 and Objective The aim of this study was to summarise the 29–64%, respectively. Less than 5% of the AZD5069 dose pharmacokinetic findings from eight phase I studies in was excreted as parent drug in the urine. Elderly subjects healthy volunteers given oral AZD5069, a selective small- had 39% higher AZD5069 AUC and 21% higher C than max molecule CXCR2 antagonist. younger adults. Japanese subjects had similar or slightly Methods 240 healthy volunteers across eight phase I higher exposure to AZD5069 than Caucasian subjects. Co- studies received single (0.1–200 mg) or multiple once- or administration with ketoconazole resulted in 2.1-fold twice-daily (10–120 mg) oral AZD5069 as solution, sus- higher AUC and 1.6-fold higher C . All formulations had max pension, capsules or tablets. Pharmacokinetics were

Journal

Drugs in R&D – Springer Journals

Published: May 31, 2018

References

  • Neutrophils in chronic inflammatory airway diseases: can we target them and how?
    Gernez, Y; Tirouvanziam, R; Chanez, P
  • Therapeutic implications of ‘neutrophilic asthma’
    Nair, P; Aziz-Ur-Rehman, A; Radford, K
  • Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist
    Nicholls, D; Wiley, K; Dainty, I; MacIntosh, F; Phillips, C; Gaw, A; Kärrman, Mårdh C
  • Safety and tolerability of single doses of AZD5069 in healthy volunteers
    Wray, H; Sparrow, A
  • Safety and tolerability of AZD5069 in healthy smokers following multiple ascending doses
    Wray, H; Wilbraham, D
  • The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers
    Lorch, U; Negi, H; Tabata, H; Wray, H; Cullberg, M; Larsson, B
  • The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers
    Mant, T; Wray, H; Cullberg, M; Larsson, B
  • The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions
    Jurcevic, S; Humfrey, C; Uddin, M; Warrington, S; Larsson, B; Keen, C
  • Effects of food and age on pharmacokinetics, safety and tolerability of single doses of AZD5069
    Wray, H; Mant, T
  • Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist
    Cullberg, M
  • A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis
    Soyza, A; Pavord, I; Elborn, JS; Smith, D; Wray, H; Puu, M; Larsson, B; Stockley, R
  • The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD
    Kirsten, A; Forster, K; Radeczky, E; Linnhoff, A; Balint, B; Watz, H; Wray, H; Salkeld, L; Cullberg, M; Larsson, B
  • Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma receiving ICS/LABA therapy: a phase 2b randomised trial Lancet
    O’Byrne, P; Metev, H; Puu, M; Richter, K; Keen, C; Uddin, MK; Larsson, B; Cullberg, M; Nair, P
  • Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma
    Watz, H; Uddin, M; Pedersen, F; Kirsten, A; Goldmann, T; Stellmacher, F; Groth, E; Larsson, B; Bottcher, G; Malmgren, A; Kraan, M; Rabe, KF
  • Smoking and drug interactions
    Lucas, C; Martin, J